Last updated: 2026-09-04 21:28:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Telomir Pharmaceuticals, Inc. (TELO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.17, with a market capitalization of $77.03M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.89 to $2.09. This page covers its latest market performance, valuation, price trends and company information.
$77.03M | |
$1.17 | |
$20.72 | |
$0.89 | |
$1.16 | |
26.71K | |
-- | |
-- | |
$2.09 | |
$0.89 | |
-- | |
-- |
Telomir Pharmaceuticals, Inc. (TELO) is trading at $1.15 in after-hours trading as of 2026-09-04 20:56:00, down 1.29% ($0.01) from the regular-session close of $1.16.
After-hours trading shows how investors are pricing TELO after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Telomir Pharmaceuticals, Inc. (TELO) moved from $1.11 to $1.17, representing a gain of 4.95% ($0.05).
The stock traded between $1.15 and $1.19 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 51.99 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 23.0%
TELO is currently trading at $1.17, placing it 23.0% of the way from its 52-week low of $0.89 to its 52-week high of $2.09. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Telomir Pharmaceuticals, Inc. (TELO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.